Evaluating the Effect of a New Medication for Atopic Dermatitis

Purpose

The purpose of the study is to evaluate if a new investigational medication, Tralokinumab, works for patients with atopic dermatitis (AD). Earlier studies of Tralokinumab have shown that the medication is effective in patients with AD. This study compares the effects of Tralokinumab to a placebo (no active medicine). To evaluate how well Tralokinumab works, we will perform a range of assessments to see how the severity of AD can decrease and quality of life could be improved.

Keywords: eczema, dermatology, itch, atopic dermatitis

Study Sites

Keck School of Medicine, Los Angeles 90033

 
  • Men & Women
Age icon
18+
 

We're sorry, but this trial is no longer enrolling volunteers.

What's involved?

Study length

  • 1 year

Number of visits

  • Up to 30 visits

Prescription

  • Tralokinumab

Procedures

  • Lab Assessments

Compensation

  • Compensation is available for completion of each study visit.

Medical cost coverage

  • All study-related visits, tests, and drugs will be provided at no cost to the participant.

Why participate?

Medical advances are impossible without volunteers.

Eligibility

Must have

  • Diagnosis of atopic dermatitis (eczema)
  • 18 years or older

Can't have

    There are no exclusion criteria

Study Team

Klzgupjvszojzdlowlmy
Principal Investigator
April W. Armstrong, MD MPH

For questions about this study, contact:

We respect your privacy!

All the information you give us is stored in a secure, password protected database. All the information that you choose to share will be kept private and confidential. Read University of Southern California's Privacy Policy here.